Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20417 | 0.97 | LMNA (0.40) | LMNA | |
| SCHEMBL1760683 | 0.89 | LMNA (0.30) | LMNA | |
| SCHEMBL9345120 | 0.89 | LMNA (0.37) | LMNA | |
| SCHEMBL23199882 | 0.88 | — | — | |
| SCHEMBL8415513 | 0.88 | — | — | |
| SCHEMBL31582089 | 0.86 | LMNA (0.42) | LMNA | |
| SCHEMBL9587347 | 0.78 | — | — | |
| SCHEMBL10811845 | 0.78 | LMNA (0.36) | LMNA | |
| SCHEMBL8998782 | 0.78 | LMNA (0.36) | LMNA | |
| SCHEMBL24033677 | 0.78 | LMNA (0.32) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720212-A1 | SAFEGUARD AGENT AND USE THEREOF | Li, Haibo (CN) | 2026-04-08 | — | — | EP | claimed |
| US-20260031402-A1 | ELECTROLYTE SOLUTION, BATTERY CELL, BATTERY, AND POWER CONSUMING APPARATUS | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2026-01-29 | — | — | US | claimed |
| US-20250391919-A1 | ELECTROLYTE SOLUTION, BATTERY CELL, BATTERY, AND POWER CONSUMING APPARATUS | CONTEMPORARY AMPEREX TECHNOLOGY CO., LIMITED (CN) | 2025-12-25 | — | — | US | claimed |
| EP-4668400-A1 | ELECTROLYTE, BATTERY CELL, BATTERY AND ELECTRICAL APPARATUS | Contemporary Amperex Technology Co., Limited (CN) | 2025-12-24 | — | — | EP | claimed |
| EP-4664591-A1 | ELECTROLYTE SOLUTION, BATTERY CELL, BATTERY, AND ELECTRIC DEVICE | Contemporary Amperex Technology Co., Limited (CN) | 2025-12-17 | — | — | EP | claimed |
| US-20250286145-A1 | ELECTROLYTE, BATTERY, AND POWER-CONSUMING DEVICE | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2025-09-11 | — | — | US | claimed |
| EP-4607648-A1 | ELECTROLYTE, BATTERY AND ELECTRIC DEVICE | Contemporary Amperex Technology (Hong Kong) Limited (HK) | 2025-08-27 | — | — | EP | claimed |
| US-20250219143-A1 | ELECTROLYTE FOR SODIUM SECONDARY BATTERY, SODIUM SECONDARY BATTERY, AND ELECTRICAL APPARATUS | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2025-07-03 | — | — | US | claimed |
| EP-4579854-A1 | ELECTROLYTE FOR SODIUM SECONDARY BATTERY, SODIUM SECONDARY BATTERY, AND ELECTRICAL APPARATUS | Contemporary Amperex Technology (Hong Kong) Limited (HK) | 2025-07-02 | — | — | EP | claimed |
| US-20240390719-A1 | SAFEGUARD AGENT AND USE THEREOF | LI HAIBO (CN) | 2024-11-28 | — | — | US | claimed |
| US-6143276-A | ADMINISTERING TO THE PATIENT A COMPOSITION COMPRISING A BIOACTIVE AGENT AND A GASEOUS PRECURSOR CAPABLE OF UNDERGOING PHASE TRANSITION TO A GAS AT A REGION OF ELEVATED TEMPERATURE IN THE PATIENT | IMARX PHARMACEUTICAL CORP. (US) | 2000-11-07 | — | — | US | claimed |
| EP-1039834-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 2000-10-04 | — | — | EP | claimed |
| EP-1037673-A1 | CHARGED LIPIDS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-09-27 | — | — | EP | claimed |
| US-6123923-A | ADMINISTERING A PATIENT A CONTRAST AGENT CONTAINING A STABILIZER, A PHOTOACTIVE AGENT, A GASEOUS PRECURSOR SUCH AS PERFLUORINATED COMPOUND OR GAS OR BOTH, AND SCANNING THE PATIENT USING ULTRASOUND IMAGING AND OPTICAL IMAGING | IMARX PHARMACEUTICAL CORP. (US) | 2000-09-26 | — | — | US | claimed |
| US-6120751-A | CONTRAST AGENT | IMARX PHARMACEUTICAL CORP. (US) | 2000-09-19 | — | — | US | claimed |
| EP-0988061-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-29 | — | — | EP | claimed |
| WO-1999030620-A1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP. (US) | 1999-06-24 | — | — | WO | claimed |
| EP-0901793-A1 | Thermal preactivation of gaseous precursor filled compositions | IMARX PHARMACEUTICAL CORP. (US) | 1999-03-17 | — | — | EP | claimed |
| WO-1998042384-A1 | METHODS FOR DELIVERING BIOACTIVE AGENTS | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | claimed |
| WO-1998042383-A1 | CHARGED LIPIDS AND USES FOR THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-10-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250391919-A1 | ELECTROLYTE SOLUTION, BATTERY CELL, BATTERY, AND POWER CONSUMING APPARATUS | HCN1, NHERF1, HCN2 | LMNA 1108/4885 |
| US-20240390719-A1 | SAFEGUARD AGENT AND USE THEREOF | BAX, CASP8, BCL2 | LMNA 2980/4885 |
| US-20260031402-A1 | ELECTROLYTE SOLUTION, BATTERY CELL, BATTERY, AND POWER CONSUMING APPARATUS | HCN1, HCN2, SLC9A1 | LMNA 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.